Forget Antibodies. Use Aptamers!™ Forget Antibodies. Use Aptamers!™
R&D Inquiry Quote
Contact Us

Apta-Services (R&D Support)

Complete this 4-step form to receive a PDF Quote on your project Cost & Time.

Intellectual Property (IP):

Aptagen owns the proprietary process of aptamer development; however, the Client will own 100% of the rights to the aptamers Aptagen develops for the Client. Client contracts Aptagen to perform the R&D, the Client owns the IP.

PRICE MATCH GUARANTEE: Contact Us. We will make every effort to match any competitor’s quote (for equivalent services).  Just provide documentation.  Thank you.

Step 1 Select a Target Type

Thank you for contacting Aptagen regarding your aptamer development needs. We can develop aptamers against your target(s) of interest. The target sample(s) do not have to be pure; crude target sample(s) are acceptable (see Additional Notes).

Depending on Client needs, the project may be tailored to meet certain milestone objectives such as:

  • High Affinity (Kd) AND High Specificity; eliminate (false-positive) cross-reactivity.
  • Wide dynamic range between positive and negative samples (LOD)
  • Activation (EC50) or inhibition (IC50) against a target enzyme
  • Identification of unknown and unique biomarkers in serum, blood, or tissue samples
  • Cell or tissue-targeting for drug delivery
  • Convert an already existing aptamer into an apta-beacon™ to detect analytes free in solution (see Apta-Beacons™)

Click on one of the below to select a target type.

Step 2 Enter Target Details

Text: Exact identity of target not needed until NDA is signed.

Step 3 Project Cost Time

Phase I: Screening/Selection

Description FAQ (138.5 KB) Target Type

Iterative rounds of screening an initial random library against a target for positive selection, and counter-selection against a counter-target for specificity. 

Client Materials: Please note that the Client will need to provide the target(s) for Aptagen. It is highly recommended that countertarget(s) is also provided for enrichment of highly specific apta-sensors. A Material Acquisition Form must be completed for background information on the target, any associated hazards, and handling requirements.

Small Targets:
Small Molecules
or Peptides
Large Targets:
Proteins, Biomarkers,
Cells, Tissues
Deliverable: The most promising monoclonal apta-sensor candidates are identified using proprietary bioinformatics. A full Progress/Analysis Report on a handful of the most likely candidates based on sequence homology, frequency, and motif analysis.
Small Molecules or Peptides Proteins or high MW Biomarkers Cell Based Ex Vivo (tissue) Whole Animal

Purity of sample target? The target sample may be crude in purity; however, an equivalent crude sample without the presence of the target is needed to perform a counter-selection before positive selection. These consecutive strategy steps effectively subtracts the influence of other endogenous components in the sample milieu and enriches for aptamer(s) against only the target in the crude sample specifically.

Discovering Unknown or Unique biomarkers using aptamers?
Yes. Contact Us for details.

Why is the apta-sensor™ approach more costly than other aptamer development methods?
This is a simple case of "you get what you pay." The apta-sensor is a far superior technology compared to conventional aptamers. Please see the comparison table on our website, or simply contact us for details.

Discounts for multiple projects? For multiple projects, a 10% discount will be applied per additional target for projects initiated simultaneously.

How to save costs to meet budget constraints? A mixture of antigens may be considered as one target, and therefore, the cost of only one project instead of the cost of multiple targets in parallel projects. However, to sort through and identify target-specific binders may result in additional cost and development time in Phase III (Validation). The cost of sorting through validation (or characterization) is nominal compared to the significant savings gained from pooling the targets in Phase I for screening.

Phase II: Sequencing and Bioinformatics

Description Deliverable
The enriched polyclonal pool is sequenced and thousands of apta-sensor sequences are provided. Client will have access to all the data generated from the polyclonal apta-sensor pool in Phase I (hundreds to thousands of sequences).
Deliverable: The most promising monoclonal apta-sensor candidates are identified using proprietary bioinformatics. A full Progress/Analysis Report on a handful of the most likely candidates based on sequence homology, frequency, and motif analysis.

Phase III: Synthesis of Candidates

Description Deliverable

Monoclonal apta-sensor oligo candidate(s) are synthesized, purified, and QC. Projects are typically based on unmodified apta-sensors. 

Note: This Phase is at the Client's discretion whether Aptagen performs the work or is performed by another provider.

Deliverable: 1 nmole of purified apta-sensors for Phase IV

Phase IV: Validation (Characterization) of Candidates

Description Assay Type:
Each tested for assessing Kd affinities, signal-to-background, LOD, targeting, or EC50/IC50, etc.. 
 
Note: This Phase is at the Client's discretion whether Aptagen performs the work or is performed by another provider.

ForteBio, Thermophoresis, Dot Blot, Gel-shift assay, or ELONA (ELISA), Microscopy, Flow Cytometry, or Imaging, etc
Deliverable: Full Report on Kd Affinities and Specificities. 

Phase V: Optimization (optional)

Description
At the Client’s discretion, Aptagen may ‘multimerize’ apta-sensors to further enhance functional properties of apta-sensor candidate(s) while truncating or minimizing the length of the oligo to reduce large-scale manufacturing costs and processing time downstream. Aptagen’s proprietary in silico algorithm searches and explores ‘sequence space.’ 
 
Inquire. Project specific. The Optimization Phase may not be necessary for research purposes. This phase entails truncation of apta-sensor oligos to reduce production costs for commercialization or ‘multimerization' of apta-sensors to further increase affinity/avidity. This Phase may trigger only if Client believes Optimization a) is cost effective to minimize production costs while maximizing activity for large-scale commercial use and/or, b) widens the claims in Client's IP to strengthen the coverage of all possible apta-sensor sequence variants.

Step 4 Enter Contact Info


Complete this 4-step form to 
receive a PDF Quote on your project Cost & Time.

Note: We do not synthesize aptamer oligos. We only specialize in developing/discovering new aptamer sequences that can be easily synthesized by any “oligo house” supplier.  Refer to our Affiliates page for oligo synthesis work.